1. Home
  2. ACET vs BEDU Comparison

ACET vs BEDU Comparison

Compare ACET & BEDU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACET
  • BEDU
  • Stock Information
  • Founded
  • ACET 1947
  • BEDU 1994
  • Country
  • ACET United States
  • BEDU United Kingdom
  • Employees
  • ACET N/A
  • BEDU N/A
  • Industry
  • ACET Biotechnology: Pharmaceutical Preparations
  • BEDU Other Consumer Services
  • Sector
  • ACET Health Care
  • BEDU Real Estate
  • Exchange
  • ACET Nasdaq
  • BEDU Nasdaq
  • Market Cap
  • ACET 60.5M
  • BEDU 54.3M
  • IPO Year
  • ACET N/A
  • BEDU 2017
  • Fundamental
  • Price
  • ACET $0.72
  • BEDU N/A
  • Analyst Decision
  • ACET Strong Buy
  • BEDU
  • Analyst Count
  • ACET 7
  • BEDU 0
  • Target Price
  • ACET $5.60
  • BEDU N/A
  • AVG Volume (30 Days)
  • ACET 679.5K
  • BEDU 1.2K
  • Earning Date
  • ACET 08-07-2025
  • BEDU 11-25-2025
  • Dividend Yield
  • ACET N/A
  • BEDU N/A
  • EPS Growth
  • ACET N/A
  • BEDU N/A
  • EPS
  • ACET N/A
  • BEDU N/A
  • Revenue
  • ACET N/A
  • BEDU $224,321,752.00
  • Revenue This Year
  • ACET N/A
  • BEDU N/A
  • Revenue Next Year
  • ACET N/A
  • BEDU N/A
  • P/E Ratio
  • ACET N/A
  • BEDU N/A
  • Revenue Growth
  • ACET N/A
  • BEDU N/A
  • 52 Week Low
  • ACET $0.45
  • BEDU $1.35
  • 52 Week High
  • ACET $1.63
  • BEDU $2.19
  • Technical
  • Relative Strength Index (RSI)
  • ACET 52.09
  • BEDU 49.14
  • Support Level
  • ACET $0.64
  • BEDU $1.76
  • Resistance Level
  • ACET $0.78
  • BEDU $1.93
  • Average True Range (ATR)
  • ACET 0.06
  • BEDU 0.04
  • MACD
  • ACET 0.01
  • BEDU 0.01
  • Stochastic Oscillator
  • ACET 68.33
  • BEDU 30.30

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

About BEDU Bright Scholar Education Holdings Limited each representing four

Bright Scholar Education Holdings Ltd operates as an education service provider. It is engaged in the provision of education services, including complementary education services, operation services for domestic schools, and education programs and services including independent schools and colleges in United Kingdom and the United States. It nearly eight overseas school located in the United Kingdom and the United States. It has three reportable segments, including Overseas Schools, Complementary Education Services, and K-12 Operation Services. Key revenue is generated from Overseas Schools. From a geographical perspective: Key revenue is generated from China following UK, U.S., Canada and Singapore.

Share on Social Networks: